NCT05315713

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who have received at least two previous lines of systemic therapy.

Conditions

• Non-Hodgkin Lymphoma, Follicular Lymphoma

Interventions

Type	Name	Description
DRUG	Mosunetuzumab SC	Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
DRUG	Tiragolumab	Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
DRUG	Atezolizumab	Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
OTHER	Tocilizumab	Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events

Timeline

• Start date: 2022-05-10
• Primary completion: 2023-07-19
• Completion: 2023-07-19
• First posted: 2022-04-07
• Last updated: 2024-10-04
• Results posted: 2024-10-04

Locations

17 sites across 6 countries: United States, Australia, Belgium, Canada, Germany, United Kingdom

Regulatory

• FDA-regulated drug study